GET DAILY SIGNALSDarioHealth (DRIO): Can It Reach the $9 Analyst Target With +445% Upside?
Key Takeaways
- The $9 central target is the arithmetic mean of four verified, current analyst price targets, which span roughly $6 to $12.
- With the latest price near $1.65, reaching $9 would require upside of about 445% — an exceptionally large move for a micro-cap stock.
- Coverage leans constructive, with three Buy ratings and one Hold, but the wide target range signals real disagreement about execution risk.
- The strongest supporting factors are the multi-condition platform, core B2B2C growth, aggressive cost reductions, and a modeled path to positive EBITDA.
- The biggest risks are soft revenue, the loss of a large Twill account, the wind-down of the biopharma business, ongoing cash burn, and dilution history.
- For more context on this ticker, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
- To discover AI-driven trade ideas, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Four current, individually attributable price targets were reviewed to build the central target. BTIG (David Larsen) initiated coverage with a Buy and a $6 target in late October 2026, while TD Cowen (Charles Rhyee) reiterated a Hold and cut its target to $8 from $11 in August 2026 after softer second-quarter revenue. Stifel (David Grossman) maintained a Buy but lowered its target to $10 from $16 in May 2026, and Alliance Global Partners (Scott Henry) initiated with a Buy and a $12 target in August 2026.
These four figures — $6, $8, $10, and $12 — average exactly $9.00, the central target used here. The range is unusually wide, from $6 to $12, which is not unusual for a small, unprofitable company where modest changes in revenue or margin assumptions move the valuation sharply. Bullish analysts emphasize the vertically integrated platform and a possible return to positive EBITDA by 2028; more cautious analysts point to softer revenue, business-mix shifts, and concentration risk. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The latest verified price is around $1.65, down sharply after recent earnings. Reaching the $9 central target would require roughly 445% upside, which must be classified as a very large move by any standard. The path would likely require a sustained re-rating rather than a single catalyst: stabilization and then growth in recurring revenue, proof that the contract pipeline converts to recognized sales, and progress toward profitability.
The company generated roughly $21 million in trailing revenue with a negative EPS of about -$2.28 and a market capitalization near $16–25 million. At such a small scale, small improvements in bookings or cost control can have outsized effects on the share price in either direction.
What Could Support a Move Toward the Target
- Multi-condition platform: Analysts see value in a single platform spanning diabetes, cardiometabolic, and obesity care, which can expand wallet share per customer.
- Core B2B2C growth: BTIG has highlighted "good core growth" in the business-to-business-to-consumer segment beneath headline figures.
- Cost discipline: Expense reductions have continued, helping narrow losses even while revenue softens.
- Profitability roadmap: Alliance Global frames DarioHealth on a multi-year path to potentially EBITDA-positive operations by 2028.
What Could Prevent the Target From Being Reached
- Revenue softness: TD Cowen's target cut followed weaker second-quarter results, and revenue growth assumptions have been revised lower.
- Account concentration: The loss of a large Twill account and the deliberate exit from the biopharma business have pressured recognized growth.
- Cash burn and dilution: The company remains unprofitable, and a 20-to-1 reverse split signals the kind of capital-structure pressure that can weigh on long-term holders.
- Valuation skepticism: Analysts have repeatedly cut fair-value estimates, reflecting lower revenue growth and higher required returns.
Technical Levels and Market Structure
DRIO's 52-week range is approximately $1.45 to $14.77, underscoring how volatile the shares have been. After the reverse split, the stock has fallen toward the lower end of that range, leaving little well-defined support below recent lows while major prior highs sit far overhead. Because the shares trade thinly with modest average volume, technical levels are less reliable than for larger names, and price moves can be exaggerated.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may differ. Investors should watch quarterly revenue trends, any updates on the contract pipeline and signed annual recurring revenue, progress on cost reductions and the path toward breakeven, and any financing or dilution announcements. Guidance revisions and analyst target changes following earnings are likely to be the most immediate drivers of the stock price. From what I see, monitoring these elements closely helps separate signal from noise in a name like this.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals have become a regular part of my workflow for names like this. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like DRIO, it offers a structured way to filter signal from noise without replacing deeper fundamental work.
Final Assessment
The $9 central target is the average of four current analyst targets, implying roughly 445% upside from a price near $1.65 — a very large move that would require a fundamental re-rating of the business. Support rests on the multi-condition platform, core B2B2C growth, cost discipline, and a modeled path to profitability, while the principal obstacles are weak revenue, account concentration, cash burn, and a wide $6-to-$12 spread of opinion. Reaching the target is possible but far from assured, and investors should watch revenue, the pipeline, and any financing developments before drawing conclusions.
Using Tickeron Tools in My Research
I regularly turn to Tickeron’s suite of AI tools when evaluating micro-cap names such as DRIO. The platform’s ability to scan patterns, generate signals, and compare peers has helped me stay organized amid the noise. In particular, the AI Daily Buy/Sell Signals feature provides an efficient layer of quantitative insight that complements traditional analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DRIO in -30.96% downward trend, declining for three consecutive days on November 12, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where DRIO declined for three days, in 281 of 312 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for DRIO entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
DRIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.422) is normal, around the industry mean (4.477). P/E Ratio (-0.160) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.386) is also within normal values, averaging (6.065).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. DRIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DRIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of technology to address the diabetic self-monitoring of blood glucose
Industry ServicestotheHealthIndustry
Advertisement